Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Authorities Clear Cepheid's Thrombophilia Test

NEW YORK (GenomeWeb News) – Health Canada has issued a medical device license for Cepheid's Xpert HemosIL FII & FV test, the molecular diagnostics maker said today.

The new assay detects Factor II and Factor V Leiden genetic variations that are associated with thrombophilia, an increase risk of blood clots. The test runs on the firm's GeneXpert platform and provides results in just over 30 minutes, said Cepheid.

Instrumentation Laboratory will market distribute the test in Canada. The firms inked a development and distribution deal two years ago covering hemostasis diagnostics, and under that pact IL gained exclusive, worldwide distribution rights for the Xpert HemosIL FII & FV test.

"Given the complexity of traditional molecular diagnostics, clinical laboratories currently may wait up to a week for FII and FV genotyping," John Bishop, CEO of Cepheid, said in a statement. "The Xpert HemosIL FII & FV test will allow Canadian laboratories to perform the test on-demand — and integrate the results with other tests — providing physicians a more comprehensive thrombophilia profile of their patients."

Filed under

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.